OBJECTIVE: To clarify the roles of hyaluronan (HA) in joint inflammation and the process of joint destruction, using 4-methylumbelliferone (4-MU), an inhibitor of HA synthesis, in a mouse model of collagen-induced arthritis (CIA) and in a monolayer culture of fibroblast-like synoviocytes (FLS) derived from patients with rheumatoid arthritis. METHODS: DAB/1J mice were immunized with type II collagen. The effects of 4-MU were evaluated by the physiologic arthritis score, paw swelling, the histologic arthritis score, and expression of matrix metalloproteinase 3 (MMP-3) and MMP-13 in chondrocytes and synovial tissue. In vitro, the effect of 4-MU on messenger RNA and protein expression of MMP-1 and MMP-3 was determined. The effects of 4-MU on HA deposition and on serum/medium concentrations of HA were analyzed using biotinylated HA binding protein staining and an HA binding assay, respectively. RESULTS: Treatment with 4-MU in mice with CIA dramatically decreased the severity of arthritis (based on the arthritis score), paw thickness, and histopathologic changes. MMP-3 and MMP-13 expression in chondrocytes and synovial cells was significantly inhibited by 4-MU in vivo. Treatment with 4-MU also inhibited MMP-1 and MMP-3 expression in tumor necrosis factor α-stimulated FLS, in a dose-dependent manner. The 4-MU-induced decreases in the serum HA concentration in mice with CIA and in "medium" and "pericellular" HA concentrations in cultured FLS support the contention that the inhibitory mechanism of 4-MU is mediated by HA suppression. CONCLUSION: Reduced disease activity induced by 4-MU in mice with CIA revealed HA to be a crucial regulator in the course of arthritis. Therefore, 4-MU is a potential therapeutic agent in arthritis, and its inhibitory mechanism is possibly mediated by suppression of HA synthesis.
OBJECTIVE: To clarify the roles of hyaluronan (HA) in joint inflammation and the process of joint destruction, using 4-methylumbelliferone (4-MU), an inhibitor of HA synthesis, in a mouse model of collagen-induced arthritis (CIA) and in a monolayer culture of fibroblast-like synoviocytes (FLS) derived from patients with rheumatoid arthritis. METHODS: DAB/1J mice were immunized with type II collagen. The effects of 4-MU were evaluated by the physiologic arthritis score, paw swelling, the histologic arthritis score, and expression of matrix metalloproteinase 3 (MMP-3) and MMP-13 in chondrocytes and synovial tissue. In vitro, the effect of 4-MU on messenger RNA and protein expression of MMP-1 and MMP-3 was determined. The effects of 4-MU on HA deposition and on serum/medium concentrations of HA were analyzed using biotinylated HA binding protein staining and an HA binding assay, respectively. RESULTS: Treatment with 4-MU in mice with CIA dramatically decreased the severity of arthritis (based on the arthritis score), paw thickness, and histopathologic changes. MMP-3 and MMP-13 expression in chondrocytes and synovial cells was significantly inhibited by 4-MU in vivo. Treatment with 4-MU also inhibited MMP-1 and MMP-3 expression in tumor necrosis factor α-stimulated FLS, in a dose-dependent manner. The 4-MU-induced decreases in the serum HA concentration in mice with CIA and in "medium" and "pericellular" HA concentrations in cultured FLS support the contention that the inhibitory mechanism of 4-MU is mediated by HA suppression. CONCLUSION: Reduced disease activity induced by 4-MU in mice with CIA revealed HA to be a crucial regulator in the course of arthritis. Therefore, 4-MU is a potential therapeutic agent in arthritis, and its inhibitory mechanism is possibly mediated by suppression of HA synthesis.
Authors: Nadine Nagy; Adi de la Zerda; Gernot Kaber; Pamela Y Johnson; Kenneth H Hu; Michael J Kratochvil; Koshika Yadava; Wenting Zhao; Yi Cui; Guadalupe Navarro; Justin P Annes; Thomas N Wight; Sarah C Heilshorn; Paul L Bollyky; Manish J Butte Journal: J Biol Chem Date: 2017-11-28 Impact factor: 5.157
Authors: Nadine Nagy; Vivekananda G Sunkari; Gernot Kaber; Sonia Hasbun; Dung N Lam; Cate Speake; Srinath Sanda; Tracey L McLaughlin; Thomas N Wight; Steven R Long; Paul L Bollyky Journal: Matrix Biol Date: 2018-09-06 Impact factor: 11.583
Authors: Hedwich F Kuipers; Mary Rieck; Irina Gurevich; Nadine Nagy; Manish J Butte; Robert S Negrin; Thomas N Wight; Lawrence Steinman; Paul L Bollyky Journal: Proc Natl Acad Sci U S A Date: 2016-01-19 Impact factor: 11.205
Authors: Nadine Nagy; Gernot Kaber; Pamela Y Johnson; John A Gebe; Anton Preisinger; Ben A Falk; Vivekananda G Sunkari; Michel D Gooden; Robert B Vernon; Marika Bogdani; Hedwich F Kuipers; Anthony J Day; Daniel J Campbell; Thomas N Wight; Paul L Bollyky Journal: J Clin Invest Date: 2015-09-14 Impact factor: 14.808
Authors: Florien Jenner; Arne IJpma; Mairead Cleary; Daphne Heijsman; Roberto Narcisi; Peter J van der Spek; Andreas Kremer; René van Weeren; Pieter Brama; Gerjo J V M van Osch Journal: Stem Cells Dev Date: 2014-06-16 Impact factor: 3.272